Comparative Analysis of DNA Repair in Stem and Nonstem Glioma Cell Cultures (original) (raw)

Abstract

It has been reported that cancer stem cells may contribute to glioma radioresistance through preferential activation of the DNA damage checkpoint response and an increase in DNA repair capacity. We have examined DNA repair in five stem and nonstem glioma cell lines. The population doubling time was significantly increased in stem compared with nonstem cells, and enhanced activation of Chk1 and Chk2 kinases was observed in untreated CD133 + compared with CD133 À cells. Neither DNA base excision or single-strand break repair nor resolution of pH2AX nuclear foci were increased in CD133 + compared with CD133 À cells. We conclude that glioma stem cells display elongated cell cycle and enhanced basal activation of checkpoint proteins that might contribute to their radioresistance, whereas enhanced DNA repair is not a common feature of these cells. (Mol Cancer Res

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (32)

  1. Hambardzumyan D, Squatrito M, Carbajal E, Holland EC. Glioma formation, cancer stem cells, and Akt signaling. Stem Cell Rev 2008;4:203 -10.
  2. Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006;7:1238 -41.
  3. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related ''self-renewal'' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008; 26:3015 -24.
  4. Jin F, Zhao L, Zhao HY, et al. Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. Neuroscience 2008;154:541 -50.
  5. Kang MK, Kang SK. Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells. Biochem Biophys Res Commun 2008;373:539 -44.
  6. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756 -760.
  7. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006;6:425 -436.
  8. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma- derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67:4010 -5.
  9. Gu ¨nther HS, Schmidt NO, Phillips HS, et al. Glioblastoma-derived stem cell- enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008;27:2897 -909.
  10. Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133- positive and CD133-negative cells in glioblastomas. Lab Invest 2008;88:808 -15.
  11. Bigner DD, Bigner SH, Ponte ´n J, et al. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 1981;40:201 -29.
  12. Bigner SH, Bullard DE, Pegram CN, Wikstrand CJ, Bigner DD. Relationship of in vitro morphologic and growth characteristics of established human glioma- derived cell lines to their tumorigenicity in athymic nude mice. J Neuropathol Exp Neurol 1981;40:390 -409.
  13. Bullard DE, Schold SC, Jr., Bigner SH, Bigner DD. Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 1981;40:410 -27.
  14. de Ridder LI, Laerum OD, Mørk SJ, Bigner DD. Invasiveness of human glioma cell lines in vitro: relation to tumorigenicity in athymic mice. Acta Neuropathol 1987;72:207 -13.
  15. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G 1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A 1998;95:15406 -11.
  16. Frosina G, Cappelli E, Ropolo M, Fortini P, Pascucci B, Dogliotti E. In vitro base excision repair assay using mammalian cell extracts. In: Henderson DS, editor. DNA repair protocols: mammalian systems. 2nd ed. Methods in molecular biology. Totowa (NJ): Humana Press; 2006. p. 377 -96.
  17. Srivastava N, Gochhait S, de Boer P, Bamezai RN. Role of H2AX in DNA damage response and human cancers. Mutat Res 2009;681:180 -8.
  18. Kinner A, Wu W, Staudt C, Iliakis G. g-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008;36:5678 -94.
  19. Zunino A, Degan P, Vigo T, Abbondandolo A. Hydrogen peroxide: effects on DNA, chromosomes, cell cycle and apoptosis induction in Fanconi's anemia cell lines. Mutagenesis 2001;16:283 -8.
  20. Enders GH. Expanded roles for Chk1 in genome maintenance. J Biol Chem 2008;283:17749 -52.
  21. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer 2007;7:925 -36.
  22. Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark 2007;3:245 -50.
  23. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007;317:337.
  24. Hill RP, Perris R. ''Destemming'' cancer stem cells. J Natl Cancer Inst 2007; 99:1435 -40.
  25. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res 2008;68:4018 -21.
  26. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275 -84.
  27. Svendsen CN, Caldwell MA, Ostenfeld T. Human neural stem cells: isolation, expansion and transplantation. Brain Pathol 1999;9:499 -513.
  28. Viaggi S, Abbondandolo A, Carbone M, et al. Uncommon cytogenetic findings in a case of splenic marginal zone lymphoma with aggressive clinical course. Cancer Genet Cytogenet 2004;148:133 -6.
  29. Ropolo M, Degan P, Foresta M, et al. Complementation of the oxidatively damaged DNA repair defect in Cockayne syndrome A and B cells by Escherichia coli formamidopyrimidine DNA glycosylase. Free Radic Biol Med 2007;42: 1807 -17.
  30. Poggi A, Pellegatta F, Leone BE. Engagement of the leukocyte- associated Ig-like receptor-1 induces programmed cell death and prevents NF-nB nuclear translocation in human myeloid leukemias. Eur J Immunol 2000; 30:2751 -2758.
  31. Glaab WE, Tindall KR. Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 1997;18:1 -8.
  32. Tanaka M, Lai JS, Herr W. Promoter-selective activation domains in Oct-1 and Oct-2 direct differential activation of an snRNA and mRNA promoter. Cell 1992;68:755 -67.